Aggressive breast cancers may be sensitive to drugs clogging their waste disposal

In a new paper in Cancer Cell, a team led by Judy Lieberman, PhD, of Boston Children's Hospital's Program in Cellular and Molecular Medicine reports "triple-negative" breast cancers may be vulnerable to drugs that attack the proteasome. This cellular structure acts as the cell's waste disposal, breaking down damaged or unneeded proteins.

These cancers, which lack the three major therapeutic markers for —the estrogen, progesterone and HER2 receptors—are very aggressive and difficult to treat. They mostly affect younger women and have the worst prognosis of all breast cancers.

By selectively turning genes off throughout the genomes of triple-negative in vitro, Lieberman's team found that these cells absolutely require active proteasomes in order to live. When turned off, the cells die.

These data suggest that triple-negative breast cancers may respond to treatment with drugs similar to bortezomib (Velcade®), a proteasome inhibitor that revolutionized the care of patients with the blood cancer .

Related Stories

Drug shows promise for triple-negative breast cancer

Jul 03, 2012

(Medical Xpress) -- A promising new therapy for hard-to-treat triple-negative breast cancer has been reported in the journal Breast Cancer Research by a team at the Tulane University School of Medicine, led by ...

Recommended for you

Low risk of malignancy for small complex adnexal masses

6 hours ago

(HealthDay)—For older women with small complex adnexal masses, the overall risk of malignancy is low, according to a study published in the December issue of the American Journal of Obstetrics & Gynecology.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.